ABIVAX Société Anonyme (BATS-CHIXE:ABVXp) - Cotización, noticias y análisis

Resumen de acción ABVXp

A clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. Saber más

Análisis fundamental de ABVXp
Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	5/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 54.33%

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 19.1% al año durante los próximos 3 años

Tiene unos ingresos inferiores a 1 millón de dólares (€20K)

Los accionistas han sido diluidos sustancialmente en el último año

Acciones altamente ilíquidas

+ 1 riesgos adicionales

Competidores de ABIVAX Société Anonyme

Avacta Group

AIM:AVCT

UK£182.9m

Oxford Biomedica

LSE:OXB

UK£447.3m

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£195.7m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de ABIVAX Société Anonyme
Precios históricos de las acciones
Precio actual de la acción	€16.22
Máximo en las últimas 52 semanas	€16.50
Mínimo de 52 semanas	€6.01
Beta	1.32
1Cambio en 1 mes	0%
Variación en 3 meses	n/a
Cambio de 1 año	110.10%
3Variación en 3 años	-26.10%
Variación en 5 años	46.65%
Variación desde la OPV	-21.57%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	ABVXp	GB Biotechs	Mercado GB
7D	0%	1.5%	2.2%
1Y	110.1%	-17.9%	8.8%

Rentabilidad vs. Industria: ABVXp superó a la industria UK Biotechs, que obtuvo un rendimiento del -17.9% el año pasado.

Rentabilidad vs. Mercado: ABVXp superó al mercado UK, que obtuvo un rendimiento del 8.8% el año pasado.

Volatilidad de los precios

Is ABVXp's price volatile compared to industry and market?
ABVXp volatility
ABVXp Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: ABVXp no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de ABVXp en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2013	26	Marc M. de Garidel	www.abivax.com

Resumen de fundamentos de ABIVAX Société Anonyme

¿Cómo se comparan los beneficios e ingresos de ABIVAX Société Anonyme con su capitalización de mercado?
Estadísticas fundamentales de ABVXp
Capitalización bursátil	€602.03m
Beneficios(TTM)	-€91.51m
Ingresos (TTM)	€20.00k

Over9,999x

Ratio precio-ventas (PS)

-6.6x

Ratio precio-beneficio (PE)

¿Está ABVXp sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ABVXp
Ingresos	€20.00k
Coste de los ingresos	€0
Beneficio bruto	€20.00k
Otros gastos	€91.53m
Beneficios	-€91.51m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.46
Margen bruto	100.00%
Margen de beneficio neto	-457,550.00%
Ratio deuda/patrimonio	50.1%

¿Cómo se ha desempeñado ABVXp a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ABVXp

Recompensas

Análisis de riesgos

Competidores de ABIVAX Société Anonyme

AIM:AVCT

UK£182.9m

LSE:OXB

UK£447.3m

LSE:GNS

UK£1.1b

AIM:BVXP

UK£195.7m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Insufficient new directors

Insufficient new directors

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Insufficient new directors

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Insufficient new directors

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €28.90

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de ABIVAX Société Anonyme

Over9,999x

-6.6x

Beneficios e Ingresos